# Yaoxing Huang

List of Publications by Year
in descending order



| | | 257357 | 434063 |
|---|---|---|---|
| 32 | 9,390 | 24 | 31 |
| papers | citations | h-index | g-index |

| | | | |
|---|---|---|---|
| 53 | 53 | 53 | 12913 |
| all docs | docs citations | times ranked | citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7. Nature, 2021, 593, 130-135. | 13.7 | 1,904 |
| 2 | Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. Nature, 2020, 584, 450-456. | 13.7 | 1,337 |
| 3 | Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2. Nature, 2022, 602, 676-681. | 13.7 | 1,038 |
| 4 | Antibody evasion properties of SARS-CoV-2 Omicron sublineages. Nature, 2022, 604, 553-556. | 13.7 | 649 |
| 5 | A Human Pluripotent Stem Cell-based Platform to Study SARS-CoV-2 Tropism and Model Virus Infection in Human Cells and Organoids. Cell Stem Cell, 2020, 27, 125-136.e7. | 5.2 | 543 |
| 6 | Antibody evasion by SARS-CoV-2 Omicron subvariants BA.2.12.1, BA.4 and BA.5. Nature, 2022, 608, 603-608. | 13.7 | 541 |
| 7 | Increased resistance of SARS-CoV-2 variant P.1 to antibody neutralization. Cell Host and Microbe, 2021, 29, 747-751.e4. | 5.1 | 504 |
| 8 | Potent SARS-CoV-2 neutralizing antibodies directed against spike N-terminal domain target a single supersite. Cell Host and Microbe, 2021, 29, 819-833.e7. | 5.1 | 444 |
| 9 | Identification of SARS-CoV-2 inhibitors using lung and colonic organoids. Nature, 2021, 589, 270-275. | 13.7 | 389 |
| 10 | Nanobodies from camelid mice and llamas neutralize SARS-CoV-2 variants. Nature, 2021, 595, 278-282. | 13.7 | 154 |
| 11 | Defining the risk of SARS-CoV-2 variants on immune protection. Nature, 2022, 605, 640-652. | 13.7 | 117 |
| 12 | SARS-CoV-2 neutralizing antibody responses are more robust in patients with severe disease. Emerging Microbes and Infections, 2020, 9, 2091-2093. | 3.0 | 109 |
| 13 | Emergence and expansion of SARS-CoV-2 B.1.526 after identification in New York. Nature, 2021, 597, 703-708. | 13.7 | 103 |
| 14 | A SARS-CoV-2 ferritin nanoparticle vaccine elicits protective immune responses in nonhuman primates. Science Translational Medicine, 2022, 14, . | 5.8 | 73 |
| 15 | Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2. Nature, 0, , . | 13.7 | 72 |
| 16 | Lead compounds for the development of SARS-CoV-2 3CL protease inhibitors. Nature Communications, 2021, 12, 2016. | 5.8 | 65 |
| 17 | Modular basis for potent SARS-CoV-2 neutralization by a prevalent VH1-2-derived antibody class. Cell Reports, 2021, 35, 108950. | 2.9 | 54 |
| 18 | Structural basis for accommodation of emerging B.1.351 and B.1.1.7 variants by two potent SARS-CoV-2 neutralizing antibodies. Structure, 2021, 29, 655-663.e4. | 1.6 | 52 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Neutralizing antibody 5-7 defines a distinct site of vulnerability in SARS-CoV-2 spike N-terminal domain. Cell Reports, 2021, 37, 109928. | 2.9 | 52 |
| 20 | Development of optimized drug-like small molecule inhibitors of the SARS-CoV-2 3CL protease for treatment of COVID-19. Nature Communications, 2022, 13, 1891. | 5.8 | 45 |
| 21 | Efficacy and breadth of adjuvanted SARS-CoV-2 receptor-binding domain nanoparticle vaccine in macaques. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, . | 3.3 | 44 |
| 22 | An Immuno-Cardiac Model for Macrophage-Mediated Inflammation in COVID-19 Hearts. Circulation Research, 2021, 129, 33-46. | 2.0 | 40 |
| 23 | Paired heavy- and light-chain signatures contribute to potent SARS-CoV-2 neutralization in public antibody responses. Cell Reports, 2021, 37, 109771. | 2.9 | 38 |
| 24 | Cardiomyocytes recruit monocytes upon SARS-CoV-2 infection by secretingÂCCL2. Stem Cell Reports, 2021, 16, 2274-2288. | 2.3 | 37 |
| 25 | An airway organoid-based screen identifies a role for the HIF1Î±-glycolysis axis in SARS-CoV-2 infection. Cell Reports, 2021, 37, 109920. | 2.9 | 36 |
| 26 | An antibody class with a common CDRH3 motif broadly neutralizes sarbecoviruses. Science Translational Medicine, 2022, 14, eabn6859. | 5.8 | 31 |
| 27 | Inhibitors of Coronavirus 3CL Proteases Protect Cells from Protease-Mediated Cytotoxicity. Journal of Virology, 2021, 95, e0237420. | 1.5 | 27 |
| 28 | A monoclonal antibody that neutralizes SARS-CoV-2 variants, SARS-CoV, and other sarbecoviruses. Emerging Microbes and Infections, 2022, 11, 147-157. | 3.0 | 25 |
| 29 | Functional differences among the spike glycoproteins of multiple emerging severe acute respiratory syndrome coronavirus 2 variants of concern. IScience, 2021, 24, 103393. | 1.9 | 17 |
| 30 | Antibody screening at reduced <scp>pH</scp> enables preferential selection of potently neutralizing antibodies targeting <scp>SARSâ€CoV</scp>â€2. AICHE Journal, 2021, 67, e17440. | 1.8 | 4 |
| 31 | Ad26.COV2.S boosts antibody and T-cell responses following BNT162b2 vaccination. Emerging Microbes and Infections, 2021, 10, 2220-2222. | 3.0 | 2 |
| 32 | Paired Heavy and Light Chain Signatures Contribute to Potent SARS-CoV-2 Neutralization in Public Antibody Responses. SSRN Electronic Journal, 0, , . | 0.4 | 1 |